Sessions cover topics from cancer vaccines to logistics and the next.
Psilera Receives Positive Preclinical in Vivo Data for Frontotemporal Dementia (FTD) Candidate, PSIL-006 | Psychedelic Invest
Bolstered by the latest preclinical data, Psilera is poised to advance their lead asset, PSIL-006, towards first-in-human studies for Frontotemporal Dementia (FTD). TAMPA, Fla., Aug.